eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free BiomanufacturingCompany to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug DiscoveryAward allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules.
eXoZymes Inc. Announces Closing of $6 Million Public OfferingLOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (
NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants.
